Redcare Pharmacy Shares Face Mounting Pressure After Disappointing Outlook

Redcare Pharmacy shares hit multi-year lows as strong Rx sales mask OTC slowdown and a sharp cut to medium-term profitability targets, sparking analyst concern.

The market's verdict on Redcare Pharmacy's latest financial update has been swift and severe. Since the March 4th release of its 2025 annual figures and 2026 guidance, the company's stock has been in a steep decline, plummeting to a multi-year low as investors digest a mixed performance and a significantly reduced profitability forecast.

Revenue Growth Obscures Underlying Challenges

On the surface, the 2025 revenue figures showed robust expansion. Group sales climbed by 24.1% to reach €2.9 billion. A standout performer was the prescription (Rx) business, where revenue surged 42.6% to cross the €1 billion threshold for the first time, finishing at €1.07 billion. The German market was particularly strong, with prescription sales nearly doubling to €503 million, underscoring the accelerating adoption of the nation's digital 'E-Rezept'.

However, this impressive top-line growth masked concerning trends in other areas. The over-the-counter (OTC) segment, a key profitability driver, saw a dramatic slowdown. Its growth rate decelerated to just 9.3% in the fourth quarter, down from 19.7% in Q1. Management pointed to reduced marketing spend and a softer overall market environment as contributing factors. Furthermore, the company's gross margin contracted to 21.3%, pressured by the faster-growing but lower-margin Rx business taking a larger share of the sales mix. The adjusted EBITDA for Q4 2025 came in at €13.1 million, a figure that fell well short of the €20.1 million consensus estimate among analysts.

Guidance Cut Sparks Analyst Concern

The forward-looking statements provided by Redcare have done little to reassure the market. For the 2026 fiscal year, management projects revenue growth of 13-15%, notably below the analyst consensus expectation of approximately 17.5%. The outlook for OTC growth (8-10%) and the adjusted EBITDA margin (at least 2.5%) also trails market forecasts, which had anticipated a margin between 2.9% and 3.0%. In a more structural shift, the company revised its medium-term EBITDA margin target downward from "over 8%" to "over 5%".

This cautious guidance has elicited a varied response from financial experts. While Jefferies maintained its "Buy" rating and €150 price target, it noted that the midpoint of the 2026 EBITDA forecast sits about 19% below the current consensus. UBS took a more neutral stance, rating the shares "Neutral" with a €74 target and highlighting the persistent deceleration in OTC growth—from around 25% in 2023 to the newly projected 8-10% for 2026. Analysts at Barclays warned of significant downward pressure on consensus estimates for both the Rx and OTC divisions.

The Path Forward: Losses and Strategic Investments

Despite its rising sales, Redcare anticipates a net loss of approximately €35 million for the full 2025 year. This continuing gap between revenue expansion and bottom-line profitability remains a core challenge for the business.

On the operational front, the company is pinning hopes on efficiency gains from a new logistics center in Plze?, Czech Republic, which commenced operations in December 2025. This facility is expected to handle Austrian orders and provide capacity for up to 15 million additional OTC shipments annually. The structural growth story for the German E-Rezept business remains intact, with Redcare targeting domestic Rx revenue exceeding €670 million for 2026.

The equity's current trading price sits roughly 44% below its 200-day moving average, a stark indicator of eroded market confidence. The effectiveness of Redcare's strategic investments will face a key test on May 6th, when the company reports its Q1 2026 results. The annual general meeting scheduled for April 15th may also offer early insights into the operational trajectory for the year ahead.